Catalent acquires Juniper Pharmaceuticals
Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is acquiring Juniper Pharmaceuticals, including its Nottingham, U.K.-based Juniper Pharma Services division.
The acquisition of Juniper will expand Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network, the company said.
“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” Catalent Oral Drug Delivery president Jonathan Arnold said. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”
Catalent will continue to support Juniper’s Crinone (progesterone gel) franchise marketed by Merck KGaA outside of the U.S. Juniper’s Intravaginal Ring development pipeline was previously licensed to Daré Bioscience, and Catalent will not be involved in the further development of this program.
No comments found